Everything on this page is extracted from SEC filings and resolved to one canonical company_id, joinable to funding, M&A, board and ownership data. 158 dilution instruments · 15 distress events · 43 related-party transactions · 50 resolved people · 6 funding rounds.
| Event | Period | Detail |
|---|---|---|
| going concern | FY2025 | Net loss of $14.2M and negative operating cash flow of $10.8M |
| going concern | FY2023 | Accumulated deficit of $167,056,381 |
| going concern | FY2018 | Working-capital deficiency $9.07M, stockholders' deficit $8.64M |
| going concern | FY2015 · 2017 · 2024 | Repeated substantial-doubt disclosures |
| material weakness | 2019, 2021, 2023, 2024, 2025 | Recurring internal-control-over-financial-reporting weaknesses |
| impairment / credit loss | — | Loss on extinguishment of notes payable; outstanding debt provisioning |
| Instrument | Amount | Conv. price | Discount | Date |
|---|---|---|---|---|
| convertible note toxic | $570,000 | — | 42% | 2019-07-22 |
| convertible note toxic | $470,000 | $1.00 | — | 2019-08-30 |
| convertible note toxic | $210,750 | $0.15 | — | 2019-10-29 |
| convertible note toxic | $100,000 | $0.58 | 42% | 2019-11-14 |
| convertible note toxic | $88,000 | — | 39% | 2020-01-14 |
Sub-dollar conversion prices with 39–42% discounts to market — the classic death-spiral structure that ratchets share count down as the price falls.
| Related party | Type | Amount | Detail |
|---|---|---|---|
| Westbury (Bermuda) Ltd. | debt-for-equity | $4,480,373 | May 2015 exchange of principal + interest into shares |
| Westbury (Bermuda) Ltd. | loan | $4,000,000 | Zero-coupon note consolidating prior borrowings |
| Westbury (Bermuda) Ltd. | loan | $500,000 | 15% annual interest |
| Tuxis Trust | loan | $500,000 | 10% → 15% interest, extended |
| John M. Desmarais | stock purchase | $1,000,000 | 250,000 shares at $4.00 — and a board member (see below) |
The cross-link the graph makes: John M. Desmarais is resolved as both a director (board_member) and the counterparty to a $1M related-party stock purchase — one person_id tying the people graph to the insider-transaction lane. That connection is invisible in any single filing; MARS surfaces it because both facts hang off the same resolved person.
| Customer | % of revenue | Period |
|---|---|---|
| Cartessa Aesthetics, LLC | 100% | FY2025 |
| "the stem cell treatment company" | 100% | FY2024–2025 |
Lance Alstodt (President) · David A. Rosa · Nickolay Kukekov · John M. Desmarais (director + related-party lender) · Joel San Antonio · A. Jeffrey Radov · Paul Jude Tonna · Richard Proodian · Joseph B. Swiader · Kurt Wagner · Gloria McConnell — each a canonical person_id, cross-firm queryable.